Table 1 Baseline characteristics of patients with and without PRNN
Factor | Non-PRNN* | PRNN | Total | P value* |
|---|---|---|---|---|
5925(100%) | 53(100%) | 5978 | ||
Age (y, median) | < 0.001 | |||
< = 55 | 4767(80.5%) | 28(52.8%) | 4795(80.2%) | |
> 55 | 1158(19.5%) | 25(47.2%) | 1183(19.8%) | |
Sex | 0.536 | |||
Male | 4298(72.5%) | 41(77.4%) | 4339(72.6%) | |
Female | 1627(27.5%) | 12(22.6%) | 1639(27.4%) | |
Smoking | 0.081 | |||
No | 3859(65.1%) | 28(52.8%) | 3887(65.0%) | |
Yes | 2066(34.9%) | 25(47.2%) | 2091(35.0%) | |
Drinking | 1.000 | |||
No | 5044(85.1%) | 45(84.9%) | 5089(85.1%) | |
Yes | 881(14.9%) | 8(16.7%) | 889(14.9%) | |
Histology, WHO** | 0.628 | |||
1 | 119(2.0%) | 0(0%) | 119(2.0%) | |
2.1–2.2 | 5806(98.0%) | 53(100%) | 5856(98%) | |
Hypertension | 1.000 | |||
No | 5401(91.2%) | 49(92.5%) | 5450(91.2%) | |
Yes | 524(8.8%) | 4(7.5%) | 528(8.8%) | |
Diabetes | 0.002 | |||
No | 5714(96.4%) | 46(86.8%) | 5760(96.4%) | |
Yes | 211(3.6%) | 7(13.2%) | 218(3.6%) | |
T stage*** | < 0.001 | |||
T1-2 | 1872(31.6%) | 6(11.3%) | 1878(31.4%) | |
T3-4 | 4053(68.4%) | 47(88.7%) | 4100(68.6%) | |
N stage*** | 0.002 | |||
N0-1 | 3773(63.6%) | 30(57.1%) | 3803(63.6%) | |
N2-3 | 2152(36.4%) | 23(42.9%) | 2175(36.4%) | |
EBV DNA, copies/ml | 0.270 | |||
< = 2000 | 2952(49.8%) | 22(41.5%) | 2974(49.7%) | |
> 2000 | 2973(50.2%) | 31(58.5%) | 3004(50.3%) | |
Induction Chemotherapy | 1.000 | |||
No | 2803(47.3%) | 26(49.1%) | 2829(47.3%) | |
Yes | 3122(52.7%) | 27(50.9%) | 3149(52.7%) | |
Concurrent chemotherapy | 0.358 | |||
No | 1017(17.2%) | 6(11.3%) | 1023(17.1%) | |
Yes | 4908(82.8%) | 47(88.7%) | 4955(82.9%) | |
primary tumor volume, cm3 | < 0.001 | |||
< = 60.5 | 4188(70.7%) | 15(28.3%) | 4360(73.0%) | |
> 60.5 | 1737(29.3%) | 38(71.7%) | 1615(27.0%) | |
Radiotherapy treatment time, day | 0.005 | |||
< = 43 | 3388(57.2%) | 20(37.7%) | 3406(57.0%) | |
> 43 | 2537(42.8%) | 33(62.3%) | 2569(43.0%) | |
HGB, g/L | 0.429 | |||
< = 126.5 | 847(14.3%) | 5(9.4%) | 852(14.3%) | |
> 126.5 | 5078(85.7%) | 48(90.6%) | 5126(85.7%) | |
Dynamic ALB, g/L | 0.013 | |||
< 30 | 4231(71.4%) | 27(50.9%) | 4258(71.2%) | |
30–35 | 1354(22.9%) | 19(35.8%) | 1373(23.0%) | |
> 35 | 340(57.4%) | 7(13.2%) | 347(5.8%) | |
CRP, g/mL | 0.012 | |||
< = 2.6 | 3934(66.4%) | 26(49.1%) | 3960(66.2%) | |
> 2.6 | 1991(33.6%) | 27(50.9%) | 2018(33.8%) | |
LDH, U/L | 0.008 | |||
< = 170 | 2542(42.9%) | 13(24.5%) | 2555(42.7%) | |
> 170 | 3383(57.1%) | 40(75.5%) | 3423(57.3%) | |
Prescription doseEQD2, Gy | 0.002 | |||
< = 72.26 | 5826(98.3%) | 48(90.6%) | 5874(98.3%) | |
> 72.26 | 99(1.7%) | 5(9.4%) | 104(1.7%) | |
D0.5ccEQD2, Gy | < 0.001 | |||
< = 80.20 | 4887(84.2%) | 20(37.7%) | 5007(83.8%) | |
> 80.20 | 938(15.8%) | 33(62.3%) | 971(16.2%) | |
V77.0(V110%), % | < 0.001 | |||
< = 0.2 | 4055(68.4%) | 19(35.8%) | 4074(68.1%) | |
> 0.2 | 1870(31.6%) | 34(64.2%) | 1904(31.9%) |